首页> 外文会议>Annual Meeting of the Japanese Association for Animal Cell Technology >CONSTRUCTION OF RECOMBINANT MONOCLONAL ANTIBODY AGAINST HEPATITIS B SURFACE ANTIGEN BY PHAGE DISPLAY
【24h】

CONSTRUCTION OF RECOMBINANT MONOCLONAL ANTIBODY AGAINST HEPATITIS B SURFACE ANTIGEN BY PHAGE DISPLAY

机译:用噬菌体展示构建对乙型肝炎表面抗原的重组单克隆抗体

获取原文

摘要

Single chain antibody fragment (scFv) to surface antigen of Hepatitis B virus was generated by phage display technique. The recombinant protein contains variable regions of murine monoclonal antibody HB3 that recognizes a conformational epitope of hepatis B surface antigen. In this study, immunoglobulin gene was introduced into phagemid vector and rescue by Ml3 helper phage in E. coli TGI. Phage expression and binding activity of recombinant antibody against HBsAg was selected. Infection of E. coli HB2151 by selected recombinant phage resulted in stable, efficient expression of scFv that could be secreted into culture medium. The scFv fragment was purified by affinity chromatography and confirmed by immunoblot analysis, which yield one band of 30 kDa. The activity of recombinant scFv was detected by ELISA, which specifically bound to its cognate antigen at minimum cutoff sensitivity level of 8 ng/ml. These results indicate that specific binding of a scFv to HBsAg can be used for diagnostic purposes. Further experiments, isolated immunoglobulin gene will be cloned into adenovirus vector for transduction of the encoding cDNA into HBV infected hepatocytes and tested its ability to interfere with the HBV replication cycle that might be a novel gene therapy strategy for intracellular immunization against chronic HBV infection.
机译:通过噬菌体显示技术产生乙型肝炎病毒表面抗原的单链抗体片段(SCFV)。重组蛋白含有鼠单克隆抗体Hb3的可变区,识别肝细胞B表面抗原的构象表位。在该研究中,将免疫球蛋白基因引入噬菌虫载体中,并通过ML3辅助噬菌体在大肠杆菌TGI中拯救。选择重组抗体对HBsAg的噬菌体表达和结合活性。通过选定的重组噬菌体感染大肠杆菌HB2151导致SCFV的稳定,有效的表达,其可以分泌到培养基中。通过亲和层析纯化SCFV片段,并通过免疫印迹分析证实,其产生30kDa的一条带。 ELISA检测重组SCFV的活性,其在最小截止敏感性水平为8ng / ml的最小截止敏感水平上特别结合其同源抗原。这些结果表明,SCFV对HBsAg的特异性结合可用于诊断目的。进一步的实验,分离的免疫球蛋白基因将克隆到腺病毒载体中,以将编码cDNA转导入HBV感染的肝细胞,并测试其干扰HBV复制循环的能力,这可能是用于慢性HBV感染的细胞内免疫基因治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号